Pipeline Report 2025: Late-stage programs set to reshape treatment
Drug candidates in oncology, neurology, rare diseases, and more are approaching critical development as the calendar turns to 2026.
CELMoDs (cereblon E3 ligase modulators) are oral small molecules that bind cereblon to trigger degradation of key myeloma survival proteins, directly inducing tumor-cell apoptosis, building on older immunomodulatory drugs (IMiDs).
- Iberdomide RRMM (EXCALIBER-RRMM) and mezigdomide RRMM (SUCCESSOR 1 and 2) registrational data are expected in late 2025 and early 2026.
- Peak sales predictions for the combination are approximately $5 billion by 2032.
After lingering in the BMS pipeline since the infamous $74 billion Celgene acquisition in 2019 and overshadowed by high-profile cell therapies, they’re now nearing center stage with pivotal data imminent.
These CELMoDs will be used alongside standard myeloma backbone combinations and across multiple settings, representing a large market opportunity.
Author's summary: Late-stage programs are set to reshape treatment in 2026.
More News
- Move Over Protein. Here’s One of the Hottest Food Trends for 2026, Experts Say
- The Angel Ball Honors Tina Knowles
- Open-source protein structure AI aims to match AlphaFold
- State Rep. Marcus Wiedower Resigns; Special Election Will Be Called - Flagpole
- 238,000 visitors attended Frankfurt Book Fair 2025 | PrintWeekIndia
- Al-Nassr 1-2 Al-Ittihad: Report, result and goals as Karim Benzema scores to knock Cristiano Ronaldo's side out of Kings Cup
- Atalanta v AC Milan: Confirmed line-ups as Rossoneri look to end hosts' unbeaten start
- The Coming Dementia Crisis—and the Cost of Doing Nothing
- US Embassy in Mali urges Americans to leave ‘immediately’
- The AI model OpenFold3 takes a crucial step in making protein predictions